Allianz Asset Management
SRPT icon

Allianz Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Allianz Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,760
Closed -$252K – 2088
2025
Q2 		$252K Sell
14,760
-25,661
-63% -$1.09M ﹤0.01% 1924
2025
Q1 		$2.58M Sell
40,421
-6,070
-13% -$639K ﹤0.01% 1402
2024
Q4 		$5.65M Buy
46,491
+3,012
+7% +$369K 0.01% 982
2024
Q3 		$5.43M Sell
43,479
-1,985
-4% -$274K 0.01% 1003
2024
Q2 		$7.18M Buy
45,464
+3,782
+9% +$486K 0.01% 808
2024
Q1 		$5.4M Buy
41,682
+14,474
+53% +$1.77M 0.01% 854
2023
Q4 		$2.62M Buy
27,208
+833
+3% +$79.9K ﹤0.01% 1213
2023
Q3 		$3.2M Buy
26,375
+3,142
+14% +$355K 0.01% 1194
2023
Q2 		$2.66M Buy
23,233
+15,466
+199% +$1.99M ﹤0.01% 1149
2023
Q1 		$1.07M Buy
+7,767
New +$1.01M ﹤0.01% 1658
2022
Q3 		– Sell
-6,015
Closed -$451K – 2111
2022
Q2 		$451K Hold
6,015
– – ﹤0.01% 1917
2022
Q1 		$470K Hold
6,015
– – ﹤0.01% 2123
2021
Q4 		$542K Hold
6,015
– – ﹤0.01% 2166
2021
Q3 		$556K Sell
6,015
-1,500
-20% -$116K ﹤0.01% 2191
2021
Q2 		$585K Sell
7,515
-740
-9% -$56.1K ﹤0.01% 1973
2021
Q1 		$615K Sell
8,255
-20,125
-71% -$1.86M ﹤0.01% 1821
2020
Q4 		$4.84M Buy
28,380
+5,820
+26% +$862K ﹤0.01% 1053
2020
Q3 		$3.17M Sell
22,560
-8,162
-27% -$1.24M ﹤0.01% 1115
2020
Q2 		$4.93M Buy
30,722
+1,206
+4% +$164K 0.01% 1222
2020
Q1 		$2.89M Sell
29,516
-22,888
-44% -$2.62M ﹤0.01% 1399
2019
Q4 		$6.76M Sell
52,404
-3,133
-6% -$316K 0.01% 1343
2019
Q3 		$4.18M Sell
55,537
-201,204
-78% -$23.8M ﹤0.01% 1530
2019
Q2 		$39M Buy
256,741
+3,230
+1% +$393K 0.04% 524
2019
Q1 		$30.2M Buy
253,511
+105,735
+72% +$13.6M 0.03% 586
2018
Q4 		$16.1M Buy
147,776
+62,048
+72% +$7.76M 0.02% 818
2018
Q3 		$13.8M Buy
85,728
+20,160
+31% +$2.76M 0.01% 1103
2018
Q2 		$8.67M Sell
65,568
-8,249
-11% -$778K 0.01% 1311
2018
Q1 		$5.47M Buy
73,817
+8,856
+14% +$591K 0.01% 1500
2017
Q4 		$3.62M Sell
64,961
-6,604
-9% -$350K ﹤0.01% 1774
2017
Q3 		$3.25M Sell
71,565
-586
-0.8% -$23.4K ﹤0.01% 1828
2017
Q2 		$2.41M Buy
72,151
+7,974
+12% +$260K ﹤0.01% 1913
2017
Q1 		$1.89M Buy
64,177
+3,084
+5% +$95.4K ﹤0.01% 2018
2016
Q4 		$1.68M Buy
+61,093
New +$2.45M ﹤0.01% 2039
2016
Q2 		– Sell
-79,595
Closed -$1.55M – 2607
2016
Q1 		$1.55M Sell
79,595
-185,405
-70% -$3.24M ﹤0.01% 1922
2015
Q4 		$10.2M Buy
265,000
+78,735
+42% +$2.55M 0.01% 1042
2015
Q3 		$5.98M Buy
+186,265
New +$6.32M 0.01% 1203
2014
Q3 		– Sell
-10,000
Closed -$298K – 2361
2014
Q2 		$298K Hold
10,000
– – ﹤0.01% 1715
2014
Q1 		$240K Sell
10,000
-13,000
-57% -$331K ﹤0.01% 1730
2013
Q4 		$469K Sell
23,000
-2,350
-9% -$69.8K ﹤0.01% 1557
2013
Q3 		$1.2M Sell
25,350
-52,500
-67% -$2.02M ﹤0.01% 1328
2013
Q2 		$2.96M Buy
+77,850
New +$2.78M ﹤0.01% 1065

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Allianz Asset Management's SRPT Position: Q3 2025 in Review

Allianz Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 14,760 shares — an estimated $252K sold.

Allianz Asset Management first reported a position in SRPT in Q2 2013 and held it in 41 quarters. The position peaked at $39M in Q2 2019. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Allianz Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Allianz Asset Management sold 14,760 Sarepta Therapeutics shares in Q3 2025, an estimated $252K.
  • Allianz Asset Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 41 quarters.
  • Allianz Asset Management's Sarepta Therapeutics position peaked at $39M in Q2 2019.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Allianz Asset Management's 13F filing for Q3 2025, filed 4 Nov 2025.